Taiho Pharmaceutical Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (68)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Taiho Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Taiho Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I. There are 7 cancer drugs by Taiho Pharmaceutical which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Taiho Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Taiho Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Taiho Pharmaceutical. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I. There are 7 cancer drugs by Taiho Pharmaceutical which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Taiho Pharmaceutical - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Taiho Pharmaceutical

  1.1 Business Overview

  1.2 Taiho Pharmaceutical Cancer Pipeline Overview

 

2. Taiho Pharmaceutical Cancer Drugs in Preclinical Phase

  2.1 Cancer Therapeutics - Taiho Pharmaceutical

 

3. Taiho Pharmaceutical Cancer Drugs in Phase-I

  3.1 TAS 114

  3.2 TAS 115

  3.3 TAS 119

  3.4 TAS 3681

  3.5 TAS 117

  3.6 TAS 121

 

4. Taiho Pharmaceutical Cancer Drugs in Phase-I/II

  4.1 TAS 120

 

5. Taiho Pharmaceutical Cancer Drugs in Phase-II

  5.1 TAS 116

  5.2 Mocetinostat

 

6. Taiho Pharmaceutical Cancer Drugs in Phase-III

  6.1 Gimeracil/Oteracil/Tegafur/Folinic Acid

 

7. Marketed Cancer Durgs by Taiho Pharmaceutical

  7.1 Pembrolizumab (Keytruda)

  7.2 Albumin-Bound Paclitaxel (Abraxane & Coraxane)

  7.3 Tipiracil/Trifluridine (Lonsurf)

  7.4 Trabectedin (Yondelis)

  7.5 Gimeracil/Oteracil/Tegafur (TS-1, TS-ONE & Teysuno)

  7.6 Vorinostat (Zolinza)

  7.7 Tegafur/Uracil (Orzel, Uftoral & UFT)

 

8. No Development Reported in Cancer Drugs in Clinical Pipeline

  8.1 Orantinib

  8.2 Menogaril

  8.3 BMS 247615

  8.4 Histone Deacetylase Inhibitors – MethylGene

  8.5 TPI

  8.6 TS 6

  8.7 TS 2

 

9. Discontinued in Cancer Drugs in Clinical Pipeline

  9.1 Nafamostat

  9.2 Miproxifene

  9.3 TAS 106

  9.4 Amsilarotene

  9.5 TAS 109

  9.6 C 1027

  9.7 TOP 53

  9.8 Cypemycin

  9.9 IT 62 B

  9.10 QX 102

  9.11 EUrd

  9.12 PEUdR

  9.13 QX 101


Figure 1-1: Taiho Pharmaceutical Cancer Pipeline by Phase (%)

Figure 1-2: Taiho Pharmaceutical Cancer Pipeline by Phase (Number)

Figure 1-3: Taiho Pharmaceutical Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Taiho Pharmaceutical Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)